Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Vaccine

Volumn 27, Issue 13, 2009, Pages 1974-1983

  Park, Jung Hyun ^a,b   Kim, Dae Sun ^a   Cho, Young Joo ^a   Kim, Yeon Jung ^a   Jeong, Soo Young ^a   Lee, Seung Min ^a   Cho, Seong Joo ^c   Yun, Cheol Won ^b   Jo, Inho ^d   Nam, Jae Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea University   (South Korea)

^c Chosun University   (South Korea)

^d Ewha Womans University School of Medicine   (South Korea)

Author keywords

Attenuated vaccine; Coxsackievirus; VP2

Indexed keywords

COXSACKIE VIRUS B3 VACCINE; NEUTRALIZING ANTIBODY; PHENYLALANINE; PROTEIN VP2; TYROSINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREATITIS; PRIORITY JOURNAL; PROTECTION; SURVIVAL RATE; VIRUS MUTANT; VIRUS MYOCARDITIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CONSERVED SEQUENCE; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; MYOCARDITIS; NEUTRALIZATION TESTS; PANCREATITIS; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 61349151123     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.008     Document Type: Article

References (42)

1. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99 8 (1999) 1091-1100
2. Maisch B., Ristić A.D., Hufnagel G., and Pankuweit S. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 11 2 (2002) 112-122
3. Huber S., and Ramsingh A.I. Coxsackievirus-induced pancreatitis. Viral Immunol 17 3 (2004) 358-369
4. Kim K.S., Hufnagel G., Chapman N.M., and Tracy S. The group B coxsackieviruses and myocarditis. Rev Med Virol 11 6 (2001) 355-368
5. Henke A., Jarasch N., and Wutzler P. Vaccination procedures against Coxsackievirus-induced heart disease. Expert Rev Vaccines 2 6 (2003) 805-815
6. Dan M., and Chantler J.K. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection. J Virol 79 14 (2005) 9285-9295
7. Godney E.K., Arizpe H.M., and Gaunti C.J. Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol 1 4 (1987-1988) 305-314
8. Fohlman J., Ilbäck N.G., Friman G., and Morein B. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8 4 (1990) 381-384
9. Kim J.Y., Jeon E.S., Lim B.K., Kim S.M., Chung S.K., Kim J.M., et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 23 14 (2005) 1672-1679
10. Henke A., Wagner E., Whitton J.L., Zell R., and Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol 72 10 (1998) 8327-8331
11. Henke A., Zell R., and Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antiviral Res 49 1 (2001) 49-54
12. Landau B.J., Whittier P.S., Finkelstein S.D., Alstein B., Grun J.B., Schultz M., et al. Induction of heterotypic virus resistance in adult inbred mice immunized with a variant of Coxsackievirus B3. Microb Pathog 8 4 (1990) 289-298
13. Zhang H., Morgan-Capner P., Latif N., Pandolfino Y.A., Fan W., Dunn M.J., et al. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am J Pathol 150 6 (1997) 2197-2207
14. Sawyer M.H. Enterovirus infections: diagnosis and treatment. Pediatr Infect Dis J 18 12 (1999) 1033-1039 quiz 1040
15. Knowlton K.U., Jeon E.S., Berkley N., Wessely R., and Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 70 11 (1996) 7811-7818
16. Tracy S., Tu Z., Chapman N., and Hufnagel G. Genetics of coxsackievirus B3 cardiovirulence. Eur Heart J 16 Suppl. O (1995) 15-17
17. Tracy S., Chapman N.M., Romero J., and Ramsingh A.I. Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease. Trends Microbiol 4 5 (1996) 175-179
18. Stadnick E., Dan M., Sadeghi A., and Chantler J.K. Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3. J Virol 78 24 (2004) 13987-14002
19. Kim S.M., Park J.H., Chung S.K., Kim J.Y., Hwang H.Y., Chung K.C., et al. Coxsackievirus B3 infection induces cyr61 activation via JNK to mediate cell death. J Virol 78 24 (2004) 13479-13488
20. Liu P., Aitken K., Kong Y.Y., Opavsky M.A., Martino T., Dawood F., et al. The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6 4 (2000) 429-434
21. Jeong S.Y., Ahn J., Cho Y.J., Kim Y.J., Kim D.S., Jee Y., et al. Production of cross-reactive peptide antibodies against viral capsid proteins of human enterovirus B to apply diagnostic reagent. Microbiol Immunol 51 11 (2007) 1091-1098
22. Hindiyeh M., Li Q.H., Basavappa R., Hogle J.M., and Chow M. Poliovirus mutants at histidine 195 of VP2 do not cleave VP0 into VP2 and VP4. J Virol 73 11 (1999) 9072-9079
23. He Y., Chipman P.R., Howitt J., Bator C.M., Whitt M.A., Baker T.S., et al. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol 8 10 (2001) 874-878
24. Correa P.E. The building of protein structures from alpha-carbon coordinates. Proteins 7 4 (1990) 366-377
25. Inabe K., Nishizawa M., Tajima S., Ikuta K., and Aida Y. The YXXL sequences of a transmembrane protein of bovine leukemia virus are required for viral entry and incorporation of viral envelope protein into virions. J Virol 73 2 (1999) 1293-1301
26. Arnold E., Luo M., Vriend G., Rossmann M.G., Palmenberg A.C., Parks G.D., et al. Implications of the picornavirus capsid structure for polyprotein processing. Proc Natl Acad Sci USA 84 1 (1987) 21-25
27. Matsumori A., Yamada T., Suzuki H., Matoba Y., and Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72 6 (1994) 561-566
28. Satoh M., Tamura G., Segawa I., Tashiro A., Hiramori K., and Satodate R. Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch 427 5 (1996) 503-509
29. Schmidtke M., Gluck B., Merkle I., Hofmann P., Stelzner A., and Gemsa D. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis. J Med Virol 61 4 (2000) 518-526
30. Lim B.K., Choe S.C., Shin J.O., Ho S.H., Kim J.M., Yu S.S., et al. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105 11 (2002) 1278-1281
31. Dunn J.J., Bradrick S.S., Chapman N.M., Tracy S.M., and Romero J.R. The stem loop II within the 5′ nontranslated region of clinical coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model. J Infect Dis 187 10 (2003) 1552-1561
32. Dunn J.J., Chapman N.M., Tracy S., and Romero J.R. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates:localization to the 5′ nontranslated region. J Virol 74 10 (2000) 4787-4794
33. Tu Z., Chapman N.M., Hufnagel G., Tracy S., Romero J.R., Barry W.H., et al. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region. J Virol 69 8 (1995) 4607-4618
34. He Y., Lin F., Chipman P.R., Bator C.M., Baker T.S., Shoham M., et al. Structure of decay-accelerating factor bound to echovirus 7: a virus-receptor complex. Proc Natl Acad Sci USA 99 16 (2002) 10325-10329 [Epub 2002 Jul 15]
35. Lanier L.L. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. Trends Cell Biol 16 8 (2006) 388-390
36. Knowlton K.U., and Badorff C. The immune system in viral myocarditis: maintaining the balance. Circ Res 85 6 (1999) 559-561
37. Lane J.R., Neumann D.A., Lafond-Walker A., Herskowitz A., and Rose N.R. Interleukin 1 or tumor necrosis factor can promote Coxsackie B3-induced myocarditis in resistant B10.A mice. J Exp Med 175 4 (1992) 1123-1129
38. Seko Y., Takahashi N., Yagita H., Okumura K., and Yazaki Y. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3. J Pathol 183 1 (1997) 105-108
39. Boyd J.H., Mathur S., Wang Y., Bateman R.M., and Walley K.R. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72 3 (2006) 384-393
40. Pang T., Cardosa M.J., and Guzman M.G. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85 1 (2007) 43-45
41. Fuse K., Chan G., Liu Y., Gudgeon P., Husain M., Chen M., et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112 15 (2005) 2276-2285
42. Opavsky M.A., Martino T., Rabinovitch M., Penninger J., Richardson C., Petric M., et al. ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 109 12 (2002) 1561-1569